Co-administration of Favipiravir and the Remdesivir Metabolite GS-441524 Effectively Reduces SARS-CoV-2 Replication in the Lungs of the Syrian Hamster Model-Reference-Cited by-同舟云学术

Co-administration of Favipiravir and the Remdesivir Metabolite GS-441524 Effectively Reduces SARS-CoV-2 Replication in the Lungs of the Syrian Hamster Model

Published:2022-02-22 Issue:1 Volume:13 Page:
ISSN:2150-7511
Container-title:mBio
language:en
Short-container-title:mBio

Author:

Chiba Shiho¹,Kiso Maki²,Nakajima Noriko³,Iida Shun³^ORCID,Maemura Tadashi²,Kuroda Makoto¹,Sato Yuko³,Ito Mutsumi²,Okuda Moe²,Yamada Shinya²,Iwatsuki-Horimoto Kiyoko²^ORCID,Watanabe Tokiko⁴,Imai Masaki²,Armbrust Tammy¹,Baric Ralph S.⁵^ORCID,Halfmann Peter J.¹,Suzuki Tadaki³,Kawaoka Yoshihiro¹²^ORCID

Affiliation:

1. Influenza Research Institute, Department of Pathobiological Sciences, School of Veterinary Medicine, University of Wisconsin-Madison, Wisconsin, USA

2. Division of Virology, Department of Microbiology and Immunology, Institute of Medical Science, University of Tokyo, Tokyo, Japan

3. Department of Pathology, National Institute of Infectious Diseases, Tokyo, Japan

4. Department of Molecular Virology, Research Institute for Microbial Diseases, Osaka University, Osaka, Japan

5. Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA

Abstract

During a pandemic, repurposing drugs that are approved for other diseases is a quick and realistic treatment option. In this study, we found that co-administration of favipiravir and the remdesivir metabolite GS-441524 more effectively blocked SARS-CoV-2 replication in the lungs of Syrian hamsters than either favipiravir or GS-441524 alone as part of a prophylactic or therapeutic regimen.

Funder

center for research on influenza pathogenesis

HHS | NIH | National Institute of Allergy and Infectious Diseases

Japan Agency for Medical Research and Development

Publisher

American Society for Microbiology

Subject

Virology,Microbiology

Link

https://journals.asm.org/doi/pdf/10.1128/mbio.03044-21

Reference60 articles.

1. A five-day course of ivermectin for the treatment of COVID-19 may reduce the duration of illness